A new take on growth factor signaling in tamoxifen resistance

Differences in growth factor (GF) signaling may cause the poor prognosis in some breast cancer cases. A new study, published in the open access journal BMC Medical Genomics, suggests that some estrogen receptor-positive breast cancers respond poorly to tamoxifen because of increased GF signaling.

If you want to include this story in your blog, copy and paste this formatted text:

<p><a href="http://www.physorg.com/news165005770.html">A new take on growth factor signaling in tamoxifen resistance</a></p> <p>Differences in growth factor (GF) signaling may cause the poor prognosis in some breast cancer cases. A new study, published in the open access journal <i>BMC Medical Genomics</i>, suggests that some estrogen receptor-positive breast cancers respond poorly to tamoxifen because of increased GF signaling.</p>